ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 893,98
0,00%
Dow Jones
38 868,04
0,18%
DAX
18 488,33
0,00%
Brent Oil
81,30
-0,58%
Bitcoin
67 750,32
-2,53%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Calliditas Therapeutics AB (CALT)

  7. Calliditas Therapeutics AB (CALT) Actualités

CALT

Calliditas Therapeutics AB (CALT)

Calliditas Therapeutics AB
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CALT
DateHeureSourceTitreSymboleSociété
30/05/202422h52Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CALTCalliditas Therapeutics AB
30/05/202420h20PR Newswire (US)Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathyNASDAQ:CALTCalliditas Therapeutics AB
28/05/202414h46PR Newswire (US)Calliditas Therapeutics Presents Data at the 61st European Renal Association CongressNASDAQ:CALTCalliditas Therapeutics AB
28/05/202414h09Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:CALTCalliditas Therapeutics AB
28/05/202409h17PR Newswire (US)Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei CorporationNASDAQ:CALTCalliditas Therapeutics AB
23/05/202407h55PR Newswire (US)Calliditas Q1 report, January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
16/05/202408h45PR Newswire (US)Invitation to the presentation of Calliditas´s interim report January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
15/05/202414h30PR Newswire (US)Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in StockholmNASDAQ:CALTCalliditas Therapeutics AB
15/05/202413h36PR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB
14/05/202413h52PR Newswire (US)Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in ChinaNASDAQ:CALTCalliditas Therapeutics AB
06/05/202408h16PR Newswire (US)Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibNASDAQ:CALTCalliditas Therapeutics AB
24/04/202419h35PR Newswire (US)Calliditas Therapeutics' 2023 Annual Report PublishedNASDAQ:CALTCalliditas Therapeutics AB
24/04/202409h30PR Newswire (US)Calliditas Announces Positive NefIgArd Open Label Extension ResultsNASDAQ:CALTCalliditas Therapeutics AB
18/04/202413h13PR Newswire (US)Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024NASDAQ:CALTCalliditas Therapeutics AB
09/04/202413h24PR Newswire (US)Calliditas Therapeutics to Attend Conferences in AprilNASDAQ:CALTCalliditas Therapeutics AB
08/04/202414h38PR Newswire (US)Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos AiresNASDAQ:CALTCalliditas Therapeutics AB
08/04/202409h24PR Newswire (US)Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatmentNASDAQ:CALTCalliditas Therapeutics AB
12/03/202402h28PR Newswire (US)Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®NASDAQ:CALTCalliditas Therapeutics AB
06/03/202408h38PR Newswire (US)Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®NASDAQ:CALTCalliditas Therapeutics AB
01/03/202413h43PR Newswire (US)Calliditas Therapeutics to Attend Investor Conferences in MarchNASDAQ:CALTCalliditas Therapeutics AB
21/02/202407h45PR Newswire (US)Calliditas Year-end report, January - December 2023NASDAQ:CALTCalliditas Therapeutics AB
14/02/202407h11PR Newswire (US)Invitation to the presentation of Calliditas´ Year-end report January - December 2023NASDAQ:CALTCalliditas Therapeutics AB
13/02/202417h28PR Newswire (US)Calliditas provides patent updateNASDAQ:CALTCalliditas Therapeutics AB
08/01/202408h33PR Newswire (US)Calliditas Therapeutics provides business update ahead of JP Morgan conferenceNASDAQ:CALTCalliditas Therapeutics AB
07/01/202417h21PR Newswire (US)Calliditas Therapeutics appoints Maria Törnsén as President North AmericaNASDAQ:CALTCalliditas Therapeutics AB
07/01/202417h07PR Newswire (US)Calliditas to present at JP Morgan Healthcare ConferenceNASDAQ:CALTCalliditas Therapeutics AB
27/12/202318h22PR Newswire (US)Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium CapitalNASDAQ:CALTCalliditas Therapeutics AB
21/12/202301h00Dow Jones NewsStocks to Watch: Micron, Warner Bros. Discovery, Paramount Global, Calliditas TherapeuticsNASDAQ:CALTCalliditas Therapeutics AB
20/12/202323h33Dow Jones NewsCalliditas Therapeutics Shares Rise 33% After FDA Approves TarpeyoNASDAQ:CALTCalliditas Therapeutics AB
20/12/202322h34PR Newswire (US)Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney functionNASDAQ:CALTCalliditas Therapeutics AB
 Showing the most relevant articles for your search:NASDAQ:CALT

Dernières Valeurs Consultées

AMEX
BKR
Bank Restaurant
BIT
P1LVR8
BNP Paribas Issuance
BIT
P1XVE1
NLBNPIT1XVE1 20991231 84...
COIN
RCSNBTC
USOTC
IRSMF
IRESS (PK)
NASDAQ
ONYXW
Onyx Acquisition Company I
BIT
S27847
Societe Generale Effekten
BIT
P1FBB6
BNP Paribas Issuance
NYSE
DKW
Morgan Stanley Structured Asset
ASX
A2MJOM
EU
I158T
I158T
BIT
1NOW
ServiceNow
LSE
0P1S
Tesgas
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés